CIC::DUX4 fusion sarcoma represents a rare and aggressive subtype of undifferentiated small round blue cell tumors. We report on a 23-year-old African male who developed a rapidly enlarging inferolateral left buttock nodule with ulceration. After debulking excision of the lesion, histologic sections demonstrated sheets and lobules of atypical round blue cells with significant cytologic atypia. Prominent foci of atypical mitotic figures and tissue necrosis were present. Tumoral cells stained strongly and diffusely using MDM2, vimentin, WT1 and CD99 immunohistochemical (IHC) markers. Molecular testing was performed and highlighted CIC::DUX4 gene fusion positivity, making the diagnosis of a CIC::DUX4 sarcoma (CDS). Post-surgical excision, the patient showed no disease on imaging and underwent five cycles of adjuvant chemotherapy with no recurrence observed at the eight-month follow-up. With fewer than 200 cases reported in the literature and somewhat nonspecific clinicopathologic characteristics, CIC::DUX4 sarcoma presents a diagnostic challenge. This case underlines the importance of molecular diagnostics in undifferentiated sarcomas and presents a rare primary cutaneous manifestation of CIC::DUX4 fusion sarcoma. Additionally, we provide a review of the literature to aid in recognition, diagnosis, and treatment of this rare entity.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.14748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11710901PMC

Publication Analysis

Top Keywords

cicdux4 fusion
8
fusion sarcoma
8
round blue
8
cicdux4 sarcoma
8
cicdux4
5
cic-dux4 sarcoma
4
sarcoma skin
4
rare
4
skin rare
4
rare case
4

Similar Publications

CIC::DUX4 fusion sarcoma represents a rare and aggressive subtype of undifferentiated small round blue cell tumors. We report on a 23-year-old African male who developed a rapidly enlarging inferolateral left buttock nodule with ulceration. After debulking excision of the lesion, histologic sections demonstrated sheets and lobules of atypical round blue cells with significant cytologic atypia.

View Article and Find Full Text PDF
Article Synopsis
  • CIC-DUX4 rearranged sarcoma is a challenging-to-diagnose subtype of CIC-rearranged sarcomas that features specific gene rearrangements and is associated with poor patient outcomes.
  • A case study presented involves a skin tumor exhibiting WT1 and CD99 markers, which helped confirm the diagnosis through genomic panel testing.
  • The report highlights the potential of genomic testing to aid in early diagnosis and treatment, possibly improving prognoses for patients with these difficult cancers.
View Article and Find Full Text PDF

When Sarcomas Mimic Lymphomas: A BCOR-Rearranged Sarcoma Case Report.

Cureus

February 2024

Department of Medical Oncology, Kasturba Medical College, Manipal, Manipal, IND.

This case report describes the diagnostic and therapeutic challenges faced in managing an elderly diabetic man with BCOR-rearranged sarcoma, a rare, aggressive malignancy. The patient presented with neck swelling, initially suspected to be a high-grade lymphoma but later found to be undifferentiated small round cell sarcoma. Further investigations with PET-CT revealed a mass in the lower abdomen, leading us to reconsider the prior diagnosis of non-Hodgkins' lymphoma.

View Article and Find Full Text PDF

CIC-DUX4-rearranged sarcoma (CDS) is a rare and aggressive soft tissue tumor that occurs most frequently in young adults. The key oncogenic driver of this disease is the expression of the CIC-DUX4 fusion protein as a result of chromosomal rearrangements. CIC-DUX4 displays chromatin binding properties, and is therefore believed to function as an aberrant transcription factor.

View Article and Find Full Text PDF

CIC-DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!